( January 15, 2026, 1:01 PM EST) -- SAN ANTONIO — Manufacturers of glucagon-like peptide-1 receptor agonist (GLP-1 RA) medications approved by the U.S. Food and Drug Administration violated antitrust laws by unlawfully monopolizing the market and by entering into unlawful exclusive agreements with telehealth providers, a compounding pharmacy alleges in a complaint filed Jan. 14 in a Texas federal court....